Liver injury and novel coronavirus infection: development mechanisms and clinical manifestation

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The novel coronavirus infection (COVID-19) caused by SARS-CoV-2 is characterized by a variety of clinical manifestations. As the infection spreads and the number of observations increases, it is clear that SARS-CoV-2 affects not only the respiratory tract, but also the digestive system. More than half of patients with COVID-19 have changes in the biochemical blood test, indicating liver damage. The reasons for this may be direct cytopathic or mediated immune effect, organ ischemia, the intake of drugs with potential hepatotoxic effects, onset of previously undiagnosed or worsening of the course of an existing liver disease. This article provides a brief overview of the possible etiological factors of liver damage in COVID-19 and presents its own clinical case.

全文:

受限制的访问

作者简介

Maria Livzan

Omsk State Medical University

Email: mlivzan@yandex.ru
ORCID iD: 0000-0002-6581-7017
SPIN 代码: 1961-4082
Scopus 作者 ID: 24341682600

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Omsk

Olga Gaus

Omsk State Medical University

编辑信件的主要联系方式.
Email: gaus_olga@bk.ru
ORCID iD: 0000-0001-9370-4768
SPIN 代码: 7116-8419
Scopus 作者 ID: 56598554900
Researcher ID: AAB-1979-2019

MD, Cand. Sci. (Med.), Assistant Professor

俄罗斯联邦, Omsk

Darya Gavrilenko

Omsk State Medical University

Email: gavrilenko.darigav@yandex.ru
ORCID iD: 0000-0001-5245-7190
SPIN 代码: 1435-9150
俄罗斯联邦, Omsk

参考

  1. Mao R, Liang J, Shen J, et al. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020;5(5):425–427. doi: 10.1016/S2468-1253(20)30076-5
  2. Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518–1519. doi: 10.1053/j.gastro.2020.02.054
  3. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566–574. doi: 10.1016/j.jhep.2020.04.006
  4. Wu Y, Li H, Guo X, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):621–637. doi: 10.1007/s12072-020-10074-6
  5. Hunt RH, East JE, Lanas A, et al. COVID-19 and gastrointestinal disease: implications for the gastroenterologist. Dig Dis. 2021;39(2):119–139. doi: 10.1159/000512152
  6. Zhao Y, Zhao Z, Wang Y, et al. Single-Cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756–759. doi: 10.1164/rccm.202001-0179LE
  7. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020. doi: 10.1101/2020.01.30.927806
  8. Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):97–99. (In Chinese). doi: 10.3760/cma.j.issn.1007-3418.2020.02.001
  9. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763
  10. Waseem N, Chen PH. Hypoxic hepatitis: a review and clinical update. J Clin Transl Hepatol. 2016;4(3):263–268. doi: 10.14218/JCTH.2016.00022
  11. Lightsey JM, Rockey DC. Current concepts in ischemic hepatitis. Curr Opin Gastroenterol. 2017;33(3):158–163. doi: 10.1097/MOG.0000000000000355
  12. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am J Med Sci. 1973;265(3):174–189. doi: 10.1097/00000441-197303000-00001
  13. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995;108(1):252–275. doi: 10.1016/0016-5085(95)90032-2
  14. Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal liver function tests in patients with COVID-19: Relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–1872. doi: 10.1002/hep.31480
  15. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5
  16. Genovese MC, Kremer JM, van Vollenhoven RF, et al. Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol. 2017;69(9):1751–1761. doi: 10.1002/art.40176
  17. Metawea MI, Yousif WI, Moheb I. COVID 19 and liver: An A-Z literature review. Dig Liver Dis. 2021;53(2):146–152. doi: 10.1016/j.dld.2020.09.010
  18. Yang RX, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. World J Gastroenterol. 2020;26(32):4753–4762. doi: 10.3748/wjg.v26.i32.4753
  19. Livzan MA, Akhmedov VA, Krolevets TS, et al. Informative value of non-invasive markers of liver fibrosis in patients with non-alcoholic fatty liver disease. Ter Arkh. 2016;88(12):62–68. (In Russ.). doi: 10.17116/terarkh2016881262-68

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Proposed etiology of liver injury in patients with COVID-19 [18]. SIRS — systemic inflammatory response syndrome; IL — interleukin; TNF — tumor necrosis factor

下载 (257KB)
索引源数据
3. Fig. 2. Manifestations of capillaritis and residual pityriasis rosea on the thigh surface of patient V

下载 (78KB)
索引源数据
4. Fig. 3. MRCP results of patient V

下载 (148KB)
索引源数据

版权所有 © Livzan M., Gaus O., Gavrilenko D., 2022

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.


##common.cookie##